Introduction Acute bronchiolitis is the main cause of hospitalization in children under 2 years of age, with a regular seasonality, mostly due to the respiratory syncytial virus. Objectives To describe the epidemiology of bronchiolitis hospitalizations in our center in the last 12 years, and analyze the changes in clinical characteristics, microbiology, and adverse outcomes during the SARS‐CoV‐2 pandemic. Methods Observational study including patients admitted for bronchiolitis between April 2010 and December 2021 in a Spanish tertiary paediatric hospital. Relevant demographic, clinical, microbiological, and adverse outcome variables were collected in an anonymized database. The pandemic period (April 2020 to December 2021) was compared to 2010−2015 seasons using appropriate statistical tests. Results There were 2138 bronchiolitis admissions, with a mean of 195.6 per year between 2010 and 2019 and a 2−4‐month peak between November and March. In the expected season of 2020, there was a 94.4% reduction of bronchiolitis hospitalizations, with only 11 cases admitted in the first year of the pandemic. Bronchiolitis cases increased from the summer of 2021 during a 6‐month long peak, reaching a total of 171 cases. Length of stay was significantly shorter during the pandemic, but no differences were found in clinical and microbiological characteristics or other adverse outcomes. Conclusions The SARS‐CoV‐2 pandemic has modified the seasonality of bronchiolitis hospitalizations, with a dramatic decrease in cases during the expected season of 2020−2021, and an extemporaneous summer−autumn peak in 2021 with longer duration but similar patient characteristics and risk factors.

This study assessed the microbiology, clinical syndromes, and outcomes of oncologic patients with viridans group streptococci isolated from blood cultures between January 1st, 2013 and December 31st, 2016 in a referral hospital in Mexico using the Bruker MALDI Biotyper. Antimicrobial sensitivity was determined using BD Phoenix 100 according to CLSI M100 standards. Clinical information was obtained from medical records and descriptive analysis was performed. Forty-three patients were included, 22 females and 21 males, aged 42 ± 17 years. Twenty (46.5%) patients had hematological cancer and 23 (53.5%) a solid malignancy. The viridans group streptococci isolated were Streptococcus mitis, 20 (46.5%); Streptococcus anginosus, 14 (32.6%); Streptococcus sanguinis, 7 (16.3%); and Streptococcus salivarius, 2 (4.7%). The main risk factors were pyrimidine antagonist chemotherapy in 22 (51.2%) and neutropenia in 19 (44.2%) cases, respectively. Central line associated bloodstream infection was diagnosed in 18 (41.9%) cases. Septic shock occurred in 20.9% of patients, with an overall mortality of 18.6%. Only four S. mitis revealed penicillin-resistance. Our results are similar to those of other series, identifying these bacteria as emerging pathogens with significant morbidity and mortality in oncologic patients. The MALDI-TOF system increased the rate of viridans group streptococci isolation in this population.

Introduction: Acute bronchiolitis (AB) is the main cause of hospitalization in children under two years of age, with a regular seasonality, mostly due to the respiratory syncytial virus (RSV). Objectives: To describe the epidemiology of bronchiolitis hospitalizations in our centre in the last twelve years, and analyse the changes in clinical characteristics, microbiology, and adverse outcomes during the SARS-CoV2 pandemic. Methods: Observational study including patients admitted for bronchiolitis between April 2010 and December 2021 in a Spanish tertiary paediatric hospital. Relevant demographic, clinical, microbiological, and adverse outcome variables were collected in an anonymized database. The pandemic period (April 2020 to December 2021) was compared to 2010-2015 seasons using appropriate statistical tests. Results: There were 2138 bronchiolitis admissions, with a mean of 195.6 per year between 2010-2019 and a 2–4-month peak between November and March. In the expected season of 2020, there was a 94.4% reduction of bronchiolitis hospitalizations, with only eleven cases admitted in the first year of the pandemic. Bronchiolitis cases increased from the summer of 2021 during a six-month long peak, reaching a total of 171 cases. Length of stay was significantly shorter during the pandemic, but no differences were found in clinical and microbiological characteristics or other adverse outcomes. Conclusions: The SARS-CoV2 pandemic has modified the seasonality of bronchiolitis hospitalizations, with a dramatic decrease in cases during the expected season of 2020-2021, and an extemporaneous summer-autumn peak in 2021 with longer duration but similar patient characteristics and risk factors.

Background Idiopathic granulomatous mastitis (IGM) is challenging as it is a rare disease with unknown etiology, risk factors difficult to establish, and controversies regarding its treatment. Here we describe demographic and clinical characteristics of patients with IGM diagnosed at a cancer referral center, as well as the microbial isolates and treatment. Methods We reviewed the clinical charts of patients with IGM, diagnosed from 2004 to 2019. Males were excluded. Demographic data, past medical history, signs and symptoms, clinical examination findings, radiological and microbiological results, and treatments were retrieved. Frequencies were calculated for qualitative variables and measures of central tendency and dispersion for quantitative variables. Association between categorical variables was explored with a logistic regression to identify risk factors associated with treatment response. Results Two hundred cases of IGM, with a median age of 38 years, were reviewed. Concerning past medical history data, 66 patients (33.8%) were obese; 45 (30.4%) had used hormonal therapy; 6 (3.4%) had an autoimmune disease; 158 (89.8%) had been pregnant and 100 (77.5%) had breastfed. The most common signs were skin induration (65%), a delimited mass (64.5%), and suppuration (52%). On imaging findings, 53.8% was suspicious for malignancy. Culture was performed on 88 patients (44%), 32 had a microorganism isolated, most commonly Staphylococcus spp. (n=16; 51.6%) and Corynebacterium spp. (n=7; 22.6%). The most common treatment was an antibiotic regimen (n=84, 42%). Improvement was noted with the first-line therapy in 92 patients (46%). Fourteen patients (7%) had persistent symptoms and 46 (23%), relapsed. The presence of fever (OR 11.94; CI95% 1.33-106.80; p=0.027) or induration (OR 2.78; CI95% 1.25-6.19; p=0.012) were associated with a poor response. Conclusion We describe one of the largest IGM series in Latin America, on a population similar to those from other resource-limited countries. Fever and induration were associated to a greater risk of failure to initial treatment. The isolation of Corynebacterium spp. has also been described in other series. The variation of initial therapeutic strategies is an opportunity to standardize treatment by the means of prospective studies. Disclosures All Authors: No reported disclosures.